- Conditions
- Hypercholesterolemia
- Interventions
- Vytorin, Simvastatin
- Drug
- Lead sponsor
- Bronx VA Medical Center
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- The Bronx, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–11
of 11
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Stroke, Rhabdomyolysis, Jaundice
- Interventions
- Low Dose Lovastatin, Placebo, High Dose Lovastatin
- Drug · Other
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Miami, Florida • Atlanta, Georgia + 3 more
- Conditions
- Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
- Interventions
- Trastuzumab deruxtecan, Lovastatin
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Community-acquired Pneumonia, Influenza, COVID-19
- Interventions
- Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
- Drug · Other · Biological + 1 more
- Lead sponsor
- UMC Utrecht
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 11
- States / cities
- Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
- Conditions
- Diabetic Nephropathy
- Interventions
- Lisinopril, Nifedipine, Simvastatin
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1993 – 1999
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Vitiligo
- Interventions
- Simvastatin, Placebo
- Drug
- Lead sponsor
- John Harris
- Other
- Eligibility
- 18 Years to 64 Years · Male only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Worcester, Massachusetts
- Conditions
- HDL Cholesterol
- Interventions
- Simvastatin, Atorvastatin 80 mg
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Prostate Cancer, Cardiovascular Disease
- Interventions
- Nutrition, Exercise, Smoking cessation, Statin (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin), ACE inhibitor
- Behavioral · Drug
- Lead sponsor
- McMaster University
- Other
- Eligibility
- 45 Years and older · Male only
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 4
- States / cities
- Augusta, Georgia • Kansas City, Kansas • Philadelphia, Pennsylvania + 1 more
- Conditions
- Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, Hypercholesterolemia
- Interventions
- simvastatin or ezetimibe
- Drug
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Elevated LDL Cholesterol
- Interventions
- Cardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin and ramipril),, Simvastatin
- Drug
- Lead sponsor
- Ferrer Internacional S.A.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hypercholesterolemia
- Interventions
- LY3015014, Placebo, Statin, Ezetimibe
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 527 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 15
- States / cities
- Encino, California • Lancaster, California • Spring Valley, California + 12 more